Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | ATIC | P31939 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1867923 | 0.71 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL355917 | 0.67 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL16895240 | 0.64 | — | — | |
| SCHEMBL17425088 | 0.63 | ALDH1A1 (0.30) | ALDH1A1POLBRXFP1ATIC | |
| SCHEMBL2790086 | 0.62 | TDP1 (0.31) | — | |
| SCHEMBL5752168 | 0.61 | — | — | |
| SCHEMBL336074 | 0.60 | — | — | |
| SCHEMBL4273064 | 0.58 | — | — | |
| SCHEMBL7011289 | 0.58 | ATIC (0.36) | ALDH1A1POLBRXFP1ATIC | |
| SCHEMBL5165263 | 0.58 | ALDH1A1 (0.44) | ALDH1A1POLBRXFP1ATIC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1427 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190315785-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-10-17 | — | — | US | claimed |
| US-20190077726-A1 | METHODS OF SYNTHESIZING LABELED NUCLEOSIDES | SINGULAR GENOMICS SYSTEMS INC (US) | 2019-03-14 | — | — | US | claimed |
| US-9884886-B2 | Disulfide masked prodrug compositions and methods | MERCK SHARP & DOHME (US) | 2018-02-06 | — | — | US | claimed |
| EP-1913011-B1 | OLIGONUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS INC (US) | 2016-11-02 | — | — | EP | claimed |
| US-9192621-B2 | Esters and malonates of SATE prodrugs | IDENIX PHARMACEUTICALS LLC (US) | 2015-11-24 | — | — | US | claimed |
| EP-2019834-B1 | ECTONUCLEOTIDASE INHIBITORS | UNIV BONN (DE) | 2014-07-09 | — | — | EP | claimed |
| US-20130090299-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-04-11 | — | — | US | claimed |
| US-8318701-B2 | Phosphonate analogs of HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-11-27 | — | — | US | claimed |
| US-8076310-B2 | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2011-12-13 | — | — | US | claimed |
| US-7772387-B2 | Oligonucleotides comprising a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS (US) | 2010-08-10 | — | — | US | claimed |
| EP-1140835-A1 | 3,3-BIARYLPIPERIDINE AND 2,2-BIARYLMORPHOLINE DERIVATIVES | Pfizer Products Inc. (US) | 2001-10-10 | — | — | EP | claimed |
| EP-1112255-A1 | 4,4-BIARYLPIPERIDINE DERIVATIVES WITH OPIOID RECEPTOR ACTIVITY | Pfizer Products Inc. (US) | 2001-07-04 | — | — | EP | claimed |
| US-6127533-A | SPECIFICALLY HYBRIDIZABLE WITH A SELECTED SEQUENCE OF RNA OR DNA; DIAGNOSIS OF DISEASES | ISIS PHARMACEUTICALS, INC. (US) | 2000-10-03 | — | — | US | claimed |
| EP-1038872-A1 | 4-Phenyl-4-heteroarylpiperdine derivatives as opioid receptor ligands | Pfizer Products Inc. (US) | 2000-09-27 | — | — | EP | claimed |
| WO-2000039091-A1 | 3,3-BIARYLPIPERIDINE AND 2,2-BIARYLMORPHOLINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2000-07-06 | — | — | WO | claimed |
| WO-2000014066-A1 | 4,4-BIARYLPIPERIDINE DERIVATIVES WITH OPIOID RECEPTOR ACTIVITY | PFIZER PRODUCTS INC. (US) | 2000-03-16 | — | — | WO | claimed |
| EP-0955301-A2 | 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylchloline receptors | Pfizer Products Inc. (US) | 1999-11-10 | — | — | EP | claimed |
| US-4689321-A | CYTOLYSIS, ANTITUMOR, ANTICARCINOGENIC | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1987-08-25 | — | — | US | claimed |
| US-4558047-A | ANTITUMOR AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-12-10 | — | — | US | claimed |
| EP-0123473-A2 | Morpholine derivatives, processes for the preparation thereof, the use thereof and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-10-31 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315785-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | PIK3CA, TYMP, ITPA | ALDH1A1 4577/4885POLB 146/4885RXFP1 4837/4885 |
| US-20130090299-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | PIK3CA, TYMP, ITPA | ALDH1A1 4577/4885POLB 146/4885RXFP1 4837/4885 |
| US-20190077726-A1 | METHODS OF SYNTHESIZING LABELED NUCLEOSIDES | NUDT1, DUT, PNP | ALDH1A1 1243/4885POLB 113/4885RXFP1 4680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.